Genmab — November 2020

svak

Ja, der bliver da dag for dag plads for en større stigning .....

AaBforever

Spot on...:-)

E_L

Seagen : poitive resutls from innovatTV204 support planned BLA Q1 2021. I think she said to expect a new Ph3 trial to get expedited approval

Bulder

I was expecting BLA this year

Bulder

They have to make a phase 3 to get eu approval. Randomized.

E_L

yes, however, as we were already warned no longer to anticipate additional solid tumor data for tisotumab vedotin in 2020, maybe it was logical to expect LBA delay also

E_L

i imagine they need to take a biopsy, which we were told was were there were delays due to covid?

Bulder

Det hele blev ødelagt af v
accine og dermed rotation

Bulder

Lagde ellers fint ud lige efter regnskab

E_L

yea, really bad that we got that vaccine

Bulder

E_L

it is all these retail investors that think that every meeting or call should give a spike up and are disappointed when that doesn't always happen...

Solsen

Kursen er en flad fornemmelse, der kan blive forstærket grundet den sektorrotation, der efter min bedste overbevisning er baggrunden. Genmab har leveret, men GEN1046 er stadig ikke helt soleklart det JW satte os op til tro. Det kan dog stadig komme.

Helge_LarsenPI-redaktør

Chathistorikken fungerer igen. Beklager udfaldet.

E_L

my 2 cents on 1046 safety is that i find it hard to believe 2 companies that decide together to start 9 expensive expansion cohorts in 9 different tumours must
have thought very hard about the safety profile before doing that...

E_L

find it hard to believe they HAVENT thought about safety is what i was meant to say

E_L

risks are always there, but they know what to look for (mainly liver) , the dose is relatively low
and it seems like a fair shot to try

Solsen

My concerns are not safety. Just that GEN1046 expectations were high but dataset was very small and to small to make the molecule shine.

Solsen

Epco shines and ASH will be very exciting.

Solsen

We need to wait until 2021 to se the value in GEN1046.